Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AHCY | P23526 | 3/20 | 0.72 |
| ▸ | ADORA1 | P30542 | 3/20 | 0.70 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.70 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.70 |
| ▸ | ADORA2A | P29274 | 2/20 | 0.70 |
| ▸ | ADORA2B | P29275 | 2/20 | 0.70 |
| ▸ | DPP4 | P27487 | 1/20 | 0.70 |
| ▸ | MEN1 | O00255 | 1/20 | 0.70 |
| ▸ | SLC28A1 | O00337 | 1/20 | 0.70 |
| ▸ | MAP3K7 | O43318 | 1/20 | 0.70 |
| ▸ | SLC28A2 | O43868 | 1/20 | 0.70 |
| ▸ | GAPDH | P04406 | 1/20 | 0.70 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.70 |
| ▸ | STAT6 | P42226 | 1/20 | 0.70 |
| ▸ | PI4KA | P42356 | 1/20 | 0.70 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.70 |
| ▸ | PI4K2B | Q8TCG2 | 1/20 | 0.70 |
| ▸ | DOT1L | Q8TEK3 | 1/20 | 0.70 |
| ▸ | SLC29A1 | Q99808 | 1/20 | 0.70 |
| ▸ | PI4K2A | Q9BTU6 | 1/20 | 0.70 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4870935 | 0.89 | P2RY1 (0.72) | AHCYADORA1SMN1; SMN2ADORA3ADORA2A | |
| SCHEMBL8582406 | 0.89 | P2RY1 (0.72) | AHCYADORA1SMN1; SMN2ADORA3ADORA2A | |
| SCHEMBL29936504 | 0.88 | ADORA1 (0.74) | AHCYADORA1SMN1; SMN2ADORA3ADORA2A | |
| SCHEMBL15926827 | 0.88 | ADORA1 (0.74) | AHCYADORA1SMN1; SMN2ADORA3ADORA2A | |
| SCHEMBL41361 | 0.88 | ADORA1 (0.74) | AHCYADORA1SMN1; SMN2ADORA3ADORA2A | |
| SCHEMBL384075 | 0.88 | ADORA1 (0.74) | AHCYADORA1SMN1; SMN2ADORA3ADORA2A | |
| SCHEMBL15338502 | 0.88 | ADORA1 (0.74) | AHCYADORA1SMN1; SMN2ADORA3ADORA2A | |
| SCHEMBL15338536 | 0.88 | ADORA1 (0.74) | AHCYADORA1SMN1; SMN2ADORA3ADORA2A | |
| SCHEMBL15788449 | 0.88 | ADORA1 (0.74) | AHCYADORA1SMN1; SMN2ADORA3ADORA2A | |
| SCHEMBL4944751 | 0.87 | AHCY (0.69) | AHCYADORA1SMN1; SMN2ADORA3ADORA2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1540013-B1 | EVOLVING NEW MOLECULAR FUNCTION | HARVARD COLLEGE (US) | 2015-07-08 | — | — | EP | disclosed |
| EP-1423400-B2 | EVOLVING NEW MOLECULAR FUNCTION | HARVARD COLLEGE (US) | 2013-05-22 | — | — | EP | disclosed |
| US-20120165228-A1 | EVOLVING NEW MOLECULAR FUNCTION | PRESIDENT AND FELLOWS OF HARVARD COLLEGE | 2012-06-28 | — | — | US | disclosed |
| US-8206914-B2 | Evolving new molecular function | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2012-06-26 | — | — | US | disclosed |
| US-7998904-B2 | Libraries of oligonucleotides created by genetic engineering | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2011-08-16 | — | — | US | disclosed |
| US-20110190141-A1 | Evolving New Molecular Function | PRESIDENT AND FELLOWS OF HAVARD COLLEGE (US) | 2011-08-04 | — | — | US | disclosed |
| EP-2332896-A2 | Evolving new molecular function | President and Fellows of Harvard College (US) | 2011-06-15 | — | — | EP | disclosed |
| US-7771935-B2 | Evolving new molecular function | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2010-08-10 | — | — | US | disclosed |
| US-7557068-B2 | Evolving new molecular function | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2009-07-07 | — | — | US | disclosed |
| US-7491494-B2 | Evolving new molecular function | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2009-02-17 | — | — | US | disclosed |
| US-20050142583-A1 | Evolving new molecular function | PRESIDENT AND FELLOWS OF HARVARD COLLEGE | 2005-06-30 | — | — | US | disclosed |
| EP-1540013-A2 | EVOLVING NEW MOLECULAR FUNCTION | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2005-06-15 | — | — | EP | disclosed |
| US-20050042669-A1 | Evolving new molecular function | PRESIDENT AND FELLOWS OF HARVARD COLLEGE | 2005-02-24 | — | — | US | disclosed |
| US-20050025766-A1 | Evolving new molecular function | LIU DAVID R (US) | 2005-02-03 | — | — | US | disclosed |
| EP-1423400-A4 | EVOLVING NEW MOLECULAR FUNCTION | HARVARD COLLEGE (US) | 2004-12-01 | — | — | EP | disclosed |
| US-20040180412-A1 | Evolving new molecular function | THE PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2004-09-16 | — | — | US | disclosed |
| EP-1423400-A2 | EVOLVING NEW MOLECULAR FUNCTION | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2004-06-02 | — | — | EP | disclosed |
| WO-2004016767-A2 | EVOLVING NEW MOLECULAR FUNCTION | THE PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2004-02-26 | — | — | WO | disclosed |
| US-20030113738-A1 | Evolving new molecular function | PRESIDENT AND FELLOWS OF HARVARD COLLEGE | 2003-06-19 | — | — | US | disclosed |
| WO-2002074929-A2 | EVOLVING NEW MOLECULAR FUNCTION | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2002-09-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050025766-A1 | Evolving new molecular function | POLI, PCNA, POLK | AHCY 2476/4885ADORA1 2501/4885SMN1; SMN2 3993/4885 |
| US-20120165228-A1 | EVOLVING NEW MOLECULAR FUNCTION | POLI, PCNA, POLK | AHCY 2476/4885ADORA1 2501/4885SMN1; SMN2 3993/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.